Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.72 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062949 | 0.84 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL415801 | 0.84 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL418664 | 0.84 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4190999 | 0.83 | KEAP1 (0.72) | KEAP1NFE2L2CYP19A1CHRM3CHRM2 | |
| SCHEMBL4632283 | 0.83 | KEAP1 (0.72) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198082 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2764243 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7269393 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL1235433 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3909615 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930490-A | Preparation method of glycopyrronium bromide impurity reference substance | 北京康派森医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | KEAP1 1658/4885NFE2L2 1332/4885CYP19A1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.